Irish-domiciled specialty pharmaceutical company founded in 1867 by the Mallinckrodt brothers in St Louis, Missouri, now trading as Keenova Therapeutics after its 2025 merger with Endo, developing, manufacturing and commercialising branded therapeutics in autoimmune and rare disease, neonatal critical care, acute care and pain management with about 1,600 staff.
Chưa có bình luận nào.
Để lại đánh giá & nhận xét